JPMorgan Upgrades Ariad Pharmaceuticals, Inc. To Overweight
By Benzinga Staff
November 09, 2009 6:59 AM
November 09, 2009 6:59 AM
JPMorgan upgrades Ariad Pharmaceuticals, Inc. (Nasdaq: ARIA) to Overweight. The JPMorgan analyst raised ARIA price target to $6, Ariad closed just above $2 on Friday.
On JPMorgan's upgrade, Ariad Pharmaceuticals is trading up in the pre-market. The JPMorgan analyst raised his price target ahead of Ariad'spivotal late-stage data on sarcoma drug.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
